![Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks](https://assets.technologynetworks.com/production/dynamic/images/content/309948/foundation-medicine-introduces-foundationoneliquid-the-latest-advance-in-the-companys-liquid-biopsy-309948-960x540.jpg?cb=9853130)
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks
![FoundationOne®Liquid CDx Companion Diagnostic Approved in NSCLC, Advanced Ovarian and Breast Cancer - Onco'Zine FoundationOne®Liquid CDx Companion Diagnostic Approved in NSCLC, Advanced Ovarian and Breast Cancer - Onco'Zine](https://www.oncozine.com/wp-content/uploads/2020/11/Foundation-Medicine-Liquid-CDx.png)
FoundationOne®Liquid CDx Companion Diagnostic Approved in NSCLC, Advanced Ovarian and Breast Cancer - Onco'Zine
![Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-35245-x/MediaObjects/41467_2022_35245_Fig1_HTML.png)